Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

This article was originally published in The Pink Sheet Daily

Executive Summary

After 14-month vacancy, GPhA fills its top post with National Coalition on Health Care CEO Ralph Neas, who offers coalition-building skills and long background in civil rights political work.

You may also be interested in...



GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway

The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.

Deficit Super Committee Inaction May Be Best Scenario For Biopharma

It may be a best-case scenario for the biopharmaceutical industry if the Joint Select Committee on Deficit Reduction is unable to produce a proposal by Thanksgiving to cut the federal deficit by at least $1.2 trillion over 10 years.

Patent Reform: Senate May Amend Two Provisions In House Bill

The Senate will vote on whether to limit debate on the House-passed patent reform bill when it reconvenes on Sept. 6. Senate Majority Leader Harry Reid, D-Nev., made a motion for the cloture vote before the August recess in hopes of getting a final bill through Congress quickly.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel